Letteratura scientifica selezionata sul tema "Antirétroviraux – économie"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Antirétroviraux – économie".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Antirétroviraux – économie":
Demeulemeester, R., P. Pugliese, S. Wehrlen-Pugliese, A. Certain, E. Billaud, J. Langlois, L. Cuzin et al. "Etude de l'impact économique d'un conditionnement trimestriel des antirétroviraux VIH entre 2020 et 2024 - Simulations à partir d'un modèle à agent". Journal of Epidemiology and Population Health 72 (marzo 2024): 202360. http://dx.doi.org/10.1016/j.jeph.2024.202360.
Alassani, A., AC Dovonu, AC Attinsounon, J. Gninkoun, M. Gomina, A. Wanvoegbe e Et Al. "Insuffisance pondérale et facteurs associés chez les sujets infectés par VIH sous antirétroviraux suivis à Cotonou (Bénin) en 2014". Revue Malienne d'Infectiologie et de Microbiologie, 17 novembre 2016. http://dx.doi.org/10.53597/remim.v0i0.913.
Tesi sul tema "Antirétroviraux – économie":
Papot, Emmanuelle. "Coût des traitements antirétroviraux : évaluation de l’impact d’interventions au niveau des prescripteurs et des patients : ANRS-GOTA : Gestion Optimale des Traitements Antirétroviraux". Electronic Thesis or Diss., Université Paris Cité, 2021. http://www.theses.fr/2021UNIP5253.
Abstract in English:Objectives: The main objective of this project was to evaluate the impact of a series of interventions, addressed to prescribers and patients, on the expenditure on antiretroviral therapies (ART) prescribed in the Department of Infectious and Tropical Diseases (SMIT) of the Bichat Hospital, Paris, France. The secondary objectives included the description of the antiretroviral regimens used, their price, the assessment of the knowledge, beliefs and representations regarding the price of ART, and the acceptability of such interventions, among prescribers and people living with HIV (PWH). At inception, an objective was also to monitor the sustainability of the immuno-virological response for PWH who benefited from an ART switch for economic reasons, and the absence of side effects or of an alteration of the healthcare giver-PWH relationship. Background: In 2014, the economic crisis led the French Health Insurance (Social Security) to pay more attention to the expenses generated by medicines free of charge, which included ART. Generic antiretrovirals came onto the French market, and the guidelines included the concept of ART optimisation for PWH in therapeutic success. This adaptation aimed to increase the comfort of ART intake and to decrease long-term side effects. It also tackled cost criteria, thus, introducing new challenges in the doctor-PWH relationship. Problem: With some information and actions on the proper use of ART, is it possible to curb the increase in ART expenditure without a negative impact on the effectiveness and tolerance of the treatment or on the healthcare giver-PWH relationship? Methods: An interventional before-after study, in order to evaluate the expenditure on ART before and after a series of interventions in the SMIT of Bichat, against control, was developed. The budget impact analysis and therapeutic success evaluation were supplemented with a psychosocial evaluation component based on focus groups with the prescribers and PWH of the SMIT of Bichat, and questionnaires administered to these two populations aiming at studying their perceptions around ART and their price, as well as their experience of these interventions. Results: The 2014 budget impact study at the Bichat site estimated the ARV budget at €48,280,200 and highlighted potential antiretroviral combinations that could be switched to cheaper combinations, with equal efficiency and tolerance, and adapted to the medical profile of PWH. Protease inhibitor (PI) regimens changed to drug-sparing regimen or PI-free regimens, moreover with generic antiretrovirals, were the scenarios with the largest impact in terms of budget reduction. Focus groups (organised in 2015) and questionnaires (administered in 2016) helped identify the themes of the interventions. After consultation of a group of PWH followed up at the SMIT, their healthcare givers and PWH associations, two interventions were developed (a shared-decision making guide on the choice of ART and their price, and a website calculating the price of ART). They were implemented in 2018 in the experimental site. Discussion and conclusion: The generalisability of the interventions developed and of the results of the “pre-interventions assessment” stage was discussed at a national and global level. Subsequently, the post-interventions assessment was affected by the COVID-19 pandemic. Directly, through the mobilisation of people in the fight against COVID-19, and indirectly because of the resulting public health crisis and the resilience of populations. This new context makes any comparison or observation obsolete. ANRS-GOTA was a pilot study in one site, its design, tools and interventions, created and implemented, could however be rolled-out for testing on a larger scale
Rwagitinywa, Joseph. "Mesure d'exposition, d'adhérence et d'impact économique réel des antirétroviraux génériques". Thesis, Toulouse 3, 2017. http://www.theses.fr/2017TOU30236/document.
Generic antiretroviral (ARV) drugs use in developing countries has significantly reduced the cost of and increased the access to HIV treatment which contributed to the decrease in HIV related deaths and the increase of life expectancy. WHO recommendations since 2015 suggest that antiretroviral therapy should be initiated upon discovery of HIV status, regardless of immune, virological or clinical status. Since the first generic ARVs were marketed in Europe from 2012, this should contribute to an increase in the consumption of ARVs, particularly in Europe where the incidence of HIV has remained stable for ten years. However, generic ARV drugs use in developed countries arouses as much interest as interrogations. A French study highlighted the reluctance of physicians to prescribe and patients to take generic ARVs. Our first objective was to estimate the level of exposure to generic ARVs in real life in France since their commercialization from the SNIIRAM (Système National d'Information Inter-régimes de l'Assurance Maladie) database, to define the profile of patients exposed to generics versus those likely to be exposed but who were not, and to determine the factors associated with this exposure. Substitution of brands by the available generics may increase the daily number of tablets the patient should take and consequently decrease treatment adherence, however crucial for therapeutic success. Our second objective was to assess adherence to the regimen that incorporate generic ARV drugs and compare it to that of patients likely to be switched to generic ARVs but who were not. Furthermore, simulation studies have estimated large savings due to the substitution of brand ARVs by generics in developed countries. However, this strongly depends on the level of generic use. Our third objective was to quantify the level of consumption of ARV drugs and associated expenditures in Europe over the past decade and to determine the real impact of generic ARVs use on cost reduction. This work provides new data on ARV exposure in the general population, showing the low penetration of generics since they were made available, despite treatment adherence similar to that observed under brand-names. For each study, an innovative methodological approach was developed to use the SNIIRAM databases in this area
Abrogoua, Danho Pascal. "Modélisation de la réponse antirétrovirale pour l'aide à l'optimisation thérapeutique et pharmaco-économique en Côte d'Ivoire". Phd thesis, Université Claude Bernard - Lyon I, 2011. http://tel.archives-ouvertes.fr/tel-00863137.
Abrogoua, Danho Pascal. "Modélisation de la réponse antirétrovirale pour l’aide à l’optimisation thérapeutique et pharmaco-économique en Côte d’Ivoire". Thesis, Lyon 1, 2011. http://www.theses.fr/2011LYO10316/document.
Our thesis of Clinical pharmacy is a contribution to optimize the efficiency of antiretroviral therapy (ART) by modeling methods in Côte d'Ivoire. The first study was devoted to modeling the antiretroviral response from taxonomy of CD4 counts trajectories, using a meta-learning model of biomedical markers trajectories. This model applied to the taxonomy of the CD4 counts trajectories showed its interest in the identification of distinct classes of patients with particular characteristics justifying and/or determining the specific profile of meta-trajectories of the immunological marker during treatment. The second task was an assessment of the impact of key determinants of CD4 counts meta-trajectories on various types of immune response from an explanatory model with a logistic regression equation. Antiretroviral immune responses considered were expressed in terms of absence of CD4 gain, sub-optimal gain and optimal gain of CD4 at different periods of follow-up of ART. Finally the evaluation of the efficiency of first-line antiretroviral strategies in Côte d'Ivoire, was discussed in the last part with a projective pharmaco-economic model. We conducted a preliminary exploratory study opening up prospects to encourage the implementation of comprehensive pharmaco-economic assessments by modeling in Côte d'Ivoire. This study helped to highlight the unreliable methodological sections in a pharmaco-economic modeling of first-line ART in resource-limited settings
Guillon, Marlène. "Essays in HIV Prévention". Paris, EHESS, 2015. http://www.theses.fr/2015EHES0153.
The main objective of this dissertation is to offer an economic insight in the prevention of HIV. I study individual behaviors and the way these behaviors might influence HIV incidence. Chapter 1 gathers the available empirical evidence for the concept of "prevalence elasticity" in the case of HIV and demonstrates the existence of rational behavioral reaction to the risk of HIV infection. The next two chapters aim to integrate the positive externality of antiretroviral treatments on prevention in their cost-benefit analysis. Chapter 2 investigates the epidemiological and economic effects of a large scale HIV testing and treatment policy in South Africa. The results of Chapter 2 show that the success of a large-scale HIV treatment policy depends on its implementation conditions. Chapter 3 assesses the cost-effectiveness impact of an early access to care for migrant people living with HIV in France and shows that early access to care for migrants living with HIV in France would be a cost-saving intervention. Chapter 4 focuses on the determinants of sexual behaviors among the French population and studies the role of time and risk preferences in sexual behaviors. Results of Chapter 4 demonstrate that risk aversion is positively correlated with condom use among heterosexual men while present preference is negatively correlated with condom use among MSM (men who have sex with men) and women
Hunsmann, Moritz. "Dépolitisations d'une épidémie - La lutte internationale contre le sida et les politiques de santé en Tanzanie". Phd thesis, Ecole des Hautes Etudes en Sciences Sociales (EHESS), 2013. http://tel.archives-ouvertes.fr/tel-01055458.
Baldé, Fatoumata Lamarana. "L'abandon du traitement antirétroviral chez des femmes vivant avec le VIH/sida en Guinée". Mémoire, 2013. http://www.archipel.uqam.ca/5385/1/M12753.pdf.
Libri sul tema "Antirétroviraux – économie":
Taylor, Yolanda. Battling HIV/AIDS: A decision maker's guide to the procurement of medicines and related supplies. Washington, DC: World Bank, 2004.
Flynn, Matthew B. Pharmaceutical Autonomy and Public Health in Latin America: State, Society and Industry in Brazil's AIDS Program. Routledge, 2014.
Flynn, Matthew B. Pharmaceutical Autonomy and Public Health in Latin America: State, Society and Industry in Brazil's AIDS Program. Taylor & Francis Group, 2014.
Flynn, Matthew B. Pharmaceutical Autonomy and Public Health in Latin America: State, Society and Industry in Brazil's AIDS Program. Taylor & Francis Group, 2014.
Flynn, Matthew B. Pharmaceutical Autonomy and Public Health in Latin America. Taylor & Francis Group, 2018.
Flynn, Matthew B. Pharmaceutical Autonomy and Public Health in Latin America: State, Society and Industry in Brazil's AIDS Program. Taylor & Francis Group, 2014.